| Name | GSK |
|---|---|
| Epic | GSK |
| Isin | GB00BN7SWP63 |
| Index | UK100 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1,752.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £71,152.01 | Debt ratio | n/a |
| Shares in issue | 4,063.31 | Debt-to-equity ratio | n/a |
| P/E ratio | 8.5 | Assets / equity ratio | n/a |
| Total dividends per share | 32.00p | Price to book value | n/a |
| Dividend yield | 4.5 | ROCE | 47.09 |
| Dividend cover | 2.61 | EPS growth | 3 |
| Earning per share | 63.2 | 52-week high / low | 1,264.00p / 1,764.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Q2 | 2025-08-14 | 2025-10-09 | 16.00p |
| Q1 | 2025-05-15 | 2025-07-10 | 16.00p |
| Q4 | 2025-02-20 | 2025-04-10 | 16.00p |
| Q3 | 2024-11-14 | 2025-01-09 | 15.00p |
| Q2 | 2024-08-15 | 2024-10-10 | 15.00p |
| Q1 | 2024-05-16 | 2024-07-11 | 15.00p |
| Q4 | 2024-02-22 | 2024-04-11 | 16.00p |
| Q3 | 2023-11-16 | 2024-01-11 | 14.00p |
| Q2 | 2023-08-17 | 2023-10-12 | 14.00p |
| Company name | GSK |
|---|---|
| Address | 79 New Oxford Street, London, United Kingdom, WC1A 1DG |
| Telephone | +44 (0)20 8047 5000 |
| Website | http://www.gsk.com/en-gb/ |
| Director | Position |
|---|---|
| Ms Emma Walmsley | CEO |
| Dr Jeannie Lee | Non-Executive Director |
| Mr Wendy Becker | Non-Executive Director |
| Dr Gavin Screaton | Non-Executive Director |
| Mr Hal Barron | Non-Executive Director |
| Mr Jonathan Symonds | Non-Executive Chairman |
| Mr Charles Bancroft | Senior Independent Non-Executive Director |
| Ms Julie Brown | Chief Finance Officer |
| Dr Anne Beal | Independent Non-Executive Director |
| Mr Harry (Hal) C. Dietz | Independent Non-Executive Director |
| Mr Vishal Sikka | Independent Non-Executive Director |
| Mr Elizabeth (Liz) McKee Anderson | Independent Non-Executive Director |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | 22497 | 21579 | 21364 |
| Investments and other non-current assets | 1196 | 1192 | 1541 |
| Total non-current assets | 42466 | 40361 | 39377 |
| Inventory / work in progress | 5669 | 5498 | 5146 |
| Trade and other receivables | 6836 | 7385 | 7053 |
| Cash and equivalents | 3870 | 2936 | 3723 |
| Other current assets and asset held for resale | 619 | 2749 | 693 |
| Total of all assets | 59463 | 59005 | 60146 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 21697 | 21068 | 22810 |
| Long term liabilities | 24680 | 25142 | 27240 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 46377 | 46210 | 50050 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 13086 | 12795 | 10096 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 1348 | 1348 | 1347 |
| Minority interests | -585 | -552 | -502 |
| Retained earnings | 7796 | 7239 | 4363 |
| Share premium account | 3473 | 3451 | 3440 |
| Total equity | 13086 | 12795 | 10096 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 4021 | 6745 | 6433 |
| Pre-tax profit | 3477 | 6064 | 5628 |